Recent advances in the clinical development of immune checkpoint blockade therapy.
Atefeh GhahremanlooArash SoltaniSeyed Mohamad Sadegh ModaresiSeyed Isaac HashemyPublished in: Cellular oncology (Dordrecht) (2019)
Herein, we summarize current knowledge about the role of, and the mechanisms underlying PD-1/PD-L1 signaling pathways in antitumor immune responses, with particular emphasis on clinical studies evaluating the efficacy of anti-PD-1/PD-L1 blockade in various tumor types. Preliminary clinical investigations with immune-checkpoint blockers highlight broad opportunities with a high potential to enhance antitumor immunity and, as such, to generate significant clinical responses. These preliminary successes open up new avenues towards efficient therapeutics offered to patients.